Onkologie. 2019:13(2):87-91 | DOI: 10.36290/xon.2019.017

Glioblastoma with a primitive neuronal component in a long-term surviving patient

Tomáš Jirásek1, Monika Šedivcová2, Tomáš Vaněček2,3, Petr Grossmann2, Petr Šteiner2, Lucia Fröhlichová4, Marián Švajdler ml.2,3, Jana Engelová5, Renata Emmerová6, Radim Brabec7, Vladimír Beneš III7
1 Oddělení patologie, Centrum PATOS, KN Liberec, a. s., Liberec
2 Bioptická laboratoř, s. r. o., Plzeň
3 Šiklův ústav patologie, Univerzita Karlova v Praze, Lékařská fakulta v Plzni a Fakultní nemocnice Plzeň
4 Oddělení patologie, Fakultní nemocnice L. Pasteura, Košice
5 Oddělení radiodiagnostiky, Nemocnice Jablonec nad Nisou, p. o., Jablonec nad Nisou
6 Komplexní onkologické centrum, KN Liberec, a. s., Liberec
7 Oddělení neurochirurgie, Neurocentrum, KN Liberec, a. s., Liberec

We present a case of long-term followed-up patient with radically resected IDH mutant glioblastoma with a primitive neuronal
component who has survived for 9 years with only moderate neurological complications and with a very good quality of life.
Radicality of surgical resection together with mutations of the IDH genes are prognostically favourable factors in high grade glial
neoplasms of the central nervous system.

Keywords: glioblastoma with primitive neuronal component, IDH mutation, radical resection

Published: April 5, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jirásek T, Šedivcová M, Vaněček T, Grossmann P, Šteiner P, Fröhlichová L, et al.. Glioblastoma with a primitive neuronal component in a long-term surviving patient. Onkologie. 2019;13(2):87-91. doi: 10.36290/xon.2019.017.
Download citation

References

  1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO classification ot tumours of the central nervous system (revised 4th edition). IARC: Lyon 2016.
  2. Zámečník J, Rychlý B, Švajdler M. Novinky ve WHO klasifikaci nádorů centrálního nervového systému 2016 - 2. část: Embryonální nádory CNS a ostatní skupiny nádorů (kromě difúzních gliomů). Cesk Patol 2017; 53(1): 22-28. Go to PubMed...
  3. Perry A, Miller CR, Gujrati M, et al. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathol. 2009; 19(1): 81-90. Go to original source... Go to PubMed...
  4. Joseph NM, Phillips J, Dahiya S, et al. Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Mod Pathol. 2013; 26(3): 315-326. Go to original source... Go to PubMed...
  5. Chen YT, Hsu SS, Yip CM, et al. Glioblastoma with Both Oligodendroglioma and Primitive Neuroectodermal Tumor-Like Components in a Case with 9-Year Survival. Case Rep Surg. 2018; 2018: 1382680. Go to original source... Go to PubMed...
  6. Ali S, Joseph NM, Perry A, et al. Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. J Neurooncol. 2014; 119(2): 353-360. Go to original source... Go to PubMed...
  7. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8): 765-773. Go to original source... Go to PubMed...
  8. Yen KE, Bittinger MA, Su SM, et al. Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene. 2010; 29(49): 6409-6417. Go to original source... Go to PubMed...
  9. Balss J, Meyer J, Mueller W, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116(6): 597-602. Go to original source... Go to PubMed...
  10. Song X, Andrew Allen R, et al. Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma. Int J Clin Exp Pathol. 2011; 4(7): 651-660.
  11. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012; 14(Suppl. 5): v1-49. Go to original source... Go to PubMed...
  12. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003; 17(12): 2257-2317. Go to original source... Go to PubMed...
  13. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 2000;132: 365-386. Go to original source...
  14. Ward DG, Baxter L, Gordon NS, et al. Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS One. 2016; 11(2): e0149756. Go to original source... Go to PubMed...
  15. Mohapatra G, Betensky RA, Miller ER, et al. Glioma test array for use with formalin-fixed, paraffin-embedded tissue: array comparative genomic hybridization correlates with loss of heterozygosity and fluorescence in situ hybridization. J Mol Diagn. 2006; 8(2): 268-276. Go to original source... Go to PubMed...
  16. Pollack IF, Hamilton RL, James CD, et al. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg. 2006; 105(5 Suppl): 418-424. Go to original source... Go to PubMed...
  17. Wharton SB, Lammie GA, Collie DA, et al. The significance of intratumoural neurones and neuronal differentiation in diffuse gliomas: a case series. Acta Neuropathol. 2000; 100(6): 695-700. Go to original source... Go to PubMed...
  18. Shibahara J, Fukayama M. Secondary glioblastoma with advanced neuronal immunophenotype. Virchows Arch. 2005; 447(3): 665-668. Go to original source... Go to PubMed...
  19. Konar SK, Bir SC, Maiti TK, et al. Early dural metastasis from a case of glioblastoma with primitive neuroectodermal differentiation: A case report and literature review. J Clin Neurosci. 2017; 35: 78-81. Go to original source... Go to PubMed...
  20. Alvarado AM, Salacz ME, Chamoun RB. Malignant glioma-primitive neuroectodermal tumor recurring as PNET-like only subdural collection: Case report. Surg Neurol Int. 2017; 8: 243. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.